Hematologic Malignancies Multiple Myeloma And Related Plasma Cell Disorders
Hematologic Malignancies Multiple Myeloma And Related Plasma Cell Disorders Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Hematologic Malignancies Multiple Myeloma And Related Plasma Cell Disorders book. This book definitely worth reading, it is an incredibly well-written.
Hematologic Malignancies: Multiple Myeloma and Related Plasma Cell Disorders by Morie A. Gertz,Philip R. Greipp Pdf
This handbook provides up-to-date and comprehensive treatment of all plasma cell disorders, including both common and rare disorders. All disease aspects from pathogenesis to most recent therapy are covered. The text originates from the Mayo Clinic, the world's most experienced institution in plasma cell disorders. Comprehensive treatise on all plasma cell disorders from the gene level to treatment of emergencies Chapters are uniformly organized for easy data access All authors are important authorities in their field with extensive clinical experience
Hematologic Malignancies: Multiple Myeloma and Related Plasma Cell Disorders by Morie A. Gertz,Philip R. Greipp Pdf
This handbook provides up-to-date and comprehensive treatment of all plasma cell disorders, including both common and rare disorders. All disease aspects from pathogenesis to most recent therapy are covered. The text originates from the Mayo Clinic, the world's most experienced institution in plasma cell disorders. Comprehensive treatise on all plasma cell disorders from the gene level to treatment of emergencies Chapters are uniformly organized for easy data access All authors are important authorities in their field with extensive clinical experience
Multiple Myeloma and Other Plasma Cell Neoplasms by Meletios A. Dimopoulos,Thierry Facon,Evangelos Terpos Pdf
This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management.
Multiple Myeloma by Morie A. Gertz,S. Vincent Rajkumar Pdf
This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment.
Multiple Myeloma and Related Disorders by Gosta Gahrton,Brian Durie,Diana Samson Pdf
During the past decade there has been an enormous increase in knowledge of multiple myeloma and related disorders, reflected in the publication of more than 5000 articles on the subject in scientific journals. Much of this has come about as new technologies have made it possible to refine studies on chromosomes and genes and to gain information about gene expression. It is therefore highly appropriate that this new comprehensive reference should appear at this time. The book covers the whole field of multiple myeloma, and also related diseases such as Waldemström’s macroglobulinaemia, and incorporates both the basic science underlying the diseases and their clinical management. Each chapter has been written to ’stand alone’, allowing the reader to dip into a particular subject and find information quickly without the need to browse through multiple chapters. In addition to the developments described above, all of which are considered here, many other approaches to targeted therapy are reviewed.
This book deals with the diagnosis and treatment of multiple myeloma. Multiple myeloma is a plasma cell disorder, the prognosis of which has dramatically improved in the last years thanks to new immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, in relapsed/refractory disease and a diagnosis. Chapters cover such topics as prognostic and predictive factors in newly diagnosed multiple myeloma, treatment approaches, antibody therapies, and three-dimensional (3D) models mimicking multiple myeloma bone marrow–microenvironment interactions.
Multiple Myeloma and Other Plasma Cell Disorders by Bhratri BHUSHAN,DM Bhratri Bhushan MD Pdf
Multiple myeloma accounts for 1 to 2 percent of all human cancers and around 15 percent of all hematologic malignancies. The premalignant condition leading to this disorder, monoclonal gammopathy of undetermined significance is found in 3 percent of the population above 50 years of age and progresses to multiple myeloma and other dyscrasias of plasma cells at a rate of 1 percent per year. So, not only the incidence and prevalence of these disorders is high, the science of management of myeloma and other plasma cell dyscrasias has become exceedingly complex with incorporation of genetic studies in the mainstream diagnostic and treatment decision making algorithms; as well as refinement of response assessment criteria, not to mention the bewildering array of treatment choices available, new therapies continually being added to the armamentarium and paradigm shift in established practices like hematopoietic stem cell transplantation. This book encompasses the topics of multiple myeloma, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, plasma cell leukemia, mixed cryoglobulinemia syndrome, the heavy chain diseases, POEMS syndrome and amyloidosis and aims at updating and refreshing the knowledge of medical professionals as well as an easy read for non-professionals, to familiarize themselves with the concepts of plasma cell dyscrasias and thus empowering informed decision making.
This book does not provide a comprehensive overview of Multiple Myeloma but a collection of chapters with in-depth information of distinct hot topics in the diagnostic, research and therapeutic fields. The dynamics of testing new drugs for multiple myeloma treatment in clinical trials is breathtaking. Scientific discoveries have uncovered complicated pathogenesis of multiple myeloma; complicated reactions to treatment lead to the creation of super cocktails. Curability of multiple myeloma is a question that is being discussed by the entire professional myeloma world. Improvement of prognosis is a fact which is most important from a patient's perspective. We believe that this book could be of interest to medical professionals specializing in hematooncology, researchers, as well as many others.
Therapeutic options for patients with myeloma have dramatically changed over the past 10 years. Beginning with the advances in therapy resulting from the use of high-dose therapy and autologous bone marrow or stem cell tra- plant, we have more than doubled the median survival for patients as a whole, and have now have a wealth of different biology -based treatment approaches for our patients in all disease stages. This book represents state-of-the-art information from many of the leaders in the plasma cell disorders world. Sections focusing on disease pathogenesis and biology, chemotherapy-based approaches, immune -based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders provides a comprehensive collection and an excellent resource in this time of rapid change in clinical and preclinical disease knowledge. It is important to realize that these changes did not occur in a vacuum. Partnerships between academic institutions, the pharmaceutical industry, patient advocacy groups, the National Cancer Institute, community onco- gists, and ultimately our patients worked closely together to realize these advances, and to effect the radical changes in therapy we have witnessed over the past few years. This book would not have been possible without contri- tions from each of the gifted scientists and clinicians who worked tirelessly to prepare their individual chapters all the while maintaining commitment to the scientific and clinical mission of advancing care.
Plasma Cell Dyscrasias by Aldo M. Roccaro,Irene M. Ghobrial Pdf
This book provides a concise overview of the state of the art in the biology and treatment of plasma cell malignancies, a heterogeneous group of diseases primarily characterized by the presence of clonal plasma cells within the bone marrow or extramedullary sites. The plasma cell dyscrasias investigated include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, plasmacytoma, immunoglobulin deposition diseases (primary amyloidosis and systemic light and heavy chain deposition diseases), and Waldenström’s macroglobulinemia. In the case of multiple myeloma, the coverage ranges from genomic aberrations and microRNAs to treatment for different patient groups, upcoming novel therapies, immunotherapy, and transplantation. The book reflects the significant research advances achieved in this field during the past few years, which have enhanced our understanding of the molecular mechanisms responsible for the pathogenesis of plasma cell dyscrasias.
Multiple Myeloma: The second issue of Emerging Cancer Therapeutics focuses on multiple myelomas also known as plasma cell myeloma, KahlerÌs Disease and myelomatosis. It is estimated that over 20,000 new cases are diagnosed each year with over 10,000 people dying from these malignancies. Multiple myelomas are highly treatable but rarely curable. Thus it is crucial for the practitioner to be up-to-date on the latest insights regarding their management. Management options and outcomes for individuals with multiple myelomas improved dramatically with the introduction of chemotherapy. Even further improvements in prognosis have occurred because of the introduction of newer therapies such as pulse corticosteroids, thalidomide, bortezomib, and autologous and allogeneic stem cell transplantation. With the increased number of therapeutic options to choose from, the clinician is better placed to offer effective therapy but at the same time is challenged to keep abreast of the rapidly changing treatment landscape and the newly emerging data that is shaping the treatment options today and in the future. Multiple Myeloma provides a comprehensive and in-depth review of this group of malignancies. This volume reviews the current literature, provides critical evaluations of the data and offers evidence-based recommendations. About the Series: Emerging Cancer Therapeutics is an invited review publication providing a through analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging. Features of Emerging Cancer Therapeutics include: Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics Issues edited by an authority in specific subject area Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience Emphasizes multidisciplinary approaches to research and practice
Allogeneic Stem Cell Transplantation by Hillard M. Lazarus,Mary J. Laughlin Pdf
Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation.
Genetic and Molecular Epidemiology of Multiple Myeloma by Suzanne Lentzsch Pdf
Multiple myeloma is a plasma cell malignancy characterized by complex heterogenous cytogenetic abnormalities that accounts for 1.4% of all cancers, and approximately 10% of hematologic malignancies. The clinical manifestations of multiple myeloma include lytic bone lesions, cytopenia, hypercalcemia, renal dysfunction, hyperviscosity of the blood, immunodeficiency, and peripheral neuropathy. Based on the clinical and genetic data, probably all cases of multiple myeloma arise from an asymptomatic monoclonal gammopathy of unknown significance. The exact mechanism of the transition from MGUS to overt multiple myeloma is still not well understood. Recent oncogenomic studies have further advanced our understanding of the molecular pathogenesis of multiple myeloma. This book will give a comprehensive overview of the genetic and molecular epidemiology of multiple myeloma in order to get a more refined and conclusive understanding of this disease.
Multiple Myeloma - A New Era of Treatment Strategies by Klaus Podar,Kenneth C. Anderson Pdf
"Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced"
Author : Paul G. Richardson,Kenneth C. Anderson Publisher : Remedica Page : 217 pages File Size : 41,9 Mb Release : 2004 Category : Medical ISBN : 9781901346480
Multiple Myeloma by Paul G. Richardson,Kenneth C. Anderson Pdf
Multiple myeloma is the second most common hematologic malignancy, affecting 15,000 patients per year in the United States. Despite the advent of high-dose chemotherapy with stem cell transplantation, multiple myeloma remains incurable, with approximately 12,000 deaths per annum recorded in the US from the disease. Over the last 10 years, there has been a dramatic increase in our understanding of the biology of multiple myeloma, which has provided insights into mechanisms of cytotoxic resistance, both as inherent characteristics of the myeloma cell and the protective interaction between the tumor and its bone marrow microenvironment. Moreover, advances in our understanding of multiple myeloma pathogenesis have helped further define the intricacies of this complex disease. This book provides a concise overview of the state-of-the-art in multiple myeloma and should be of primary interest to clinicians as well as scientists and related caregivers alike in this rapidly changing f.